Aclasta, the drug manufactured by Novartis for the treatment of osteoporosis has received approval from the European Commission for use in men facing a high risk of fractures. Along with that, the Aclasta label has been broadened by EU to include reduction of new clinical fractures in men as well as post-menopausal women suffering from osteoporosis, who had a hip fracture recently. Known as Reclast in the United States, the once-yearly drug belongs to the category of medicines called bisphosphonates that boost bone mass, reducing fracture risk in osteoporosis patients.